Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a Healthcare company (Biotechnology) with a market capitalization of $626M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Ginkgo Bioworks Holdings, Inc. had a Maz Rating of 2.43 out of 5 (C, Hold), ranked against the other companies in its sector. Its strongest factor then was Momentum (3.58), above most of its sector; its weakest was Growth (1.64), below most of its sector. The other factors: Profitability 3.04 (around the middle of its sector); Valuation 2.84 (valued in line with its sector); Financial Health 2.25 (below most of its sector). The current rating is for members: log in to see it.
At $9.45, Ginkgo Bioworks Holdings, Inc. trades at 6.8x sales and 1.7x book value. Over the last twelve months it generated about $92M of revenue and a net loss of $258M. It runs a gross margin of 88.8%, an operating margin of -242.5% and a net margin of -249.2%. It shows return on equity of -56.9%, return on invested capital of -27.7% and a free cash flow yield of -27.1%. On the balance sheet: a debt-to-equity ratio of 1.01 and a current ratio of 4.72. Over the past 52 weeks the share price ranged from $5.37 to $18.22, with a beta of 1.75.
Ginkgo Bioworks Holdings, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 4 Buy, 3 Hold and 4 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.